During the last session, Entero Therapeutics Inc. (NASDAQ:ENTO)’s traded shares were 0.36 million, with the beta value of the company hitting 1.34. At the end of the trading day, the stock’s price was $0.47, reflecting an intraday gain of 17.41% or $0.07. The 52-week high for the ENTO share is $14.51, that puts it down -2987.23 from that peak though still a striking 59.57% gain since the share price plummeted to a 52-week low of $0.19. The company’s market capitalization is $1.53M, and the average intraday trading volume over the past 10 days was 1.4 million shares, and the average trade volume was 758.73K shares over the past three months.
Entero Therapeutics Inc. (NASDAQ:ENTO) trade information
Entero Therapeutics Inc. (ENTO) registered a 17.41% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 17.41% in intraday trading to $0.47, hitting a weekly high. The stock’s 5-day price performance is -21.29%, and it has moved by 43.03% in 30 days. Based on these gigs, the overall price performance for the year is -92.65%. The short interest in Entero Therapeutics Inc. (NASDAQ:ENTO) is 88686.0 shares and it means that shorts have 0.74 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Entero Therapeutics Inc. (ENTO) estimates and forecasts
Statistics show that Entero Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Entero Therapeutics Inc. (ENTO) shares have gone down -85.78% during the last six months, with a year-to-date growth rate more than the industry average at 97.64% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 95.90% this quarter and then jump 96.50% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 73.53%.
ENTO Dividends
Entero Therapeutics Inc. is due to release its next quarterly earnings on 2024-Oct-14. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
